Watch for FDA acceptance and priority review designation, which could come within 60 days. The ESMO 2026 Presidential Symposium presentation of SAFFRON data will provide the first detailed efficacy and safety data and is the next key catalyst.
Price Chart
Executive Summary
HUTCHMED announced that AstraZeneca has submitted a US NDA to the FDA for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET-driven EGFR-mutated NSCLC after progression on an EGFR TKI. The filing is supported by the SAFFRON Phase III trial, which showed statistically significant improvements in both PFS and OS versus platinum-based chemotherapy. This is a material regulatory milestone that could expand the addressable market for ORPATHYS into the US.
Key Facts
- AstraZeneca submitted a US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated NSCLC.
- The SAFFRON Phase III trial demonstrated statistically significant and clinically meaningful improvements in both PFS and OS versus doublet platinum-based chemotherapy.
- SAFFRON enrolled 338 patients across 230 centers in 29 countries.
- Results will be presented at the ESMO Congress 2026 Presidential Symposium.
- ORPATHYS is already approved in China for this combination, and has temporary authorization in Switzerland.
- ORPATHYS is jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
Financial Impact
US NDA submission is a major regulatory catalyst; if approved, it opens a significant new market for ORPATHYS in the US for a biomarker-defined NSCLC population with high unmet need. No financial terms or revenue figures disclosed.
Risk Factors
- FDA may require additional data or issue a Complete Response Letter (CRL).
- Competition from other MET-targeted therapies in development.
- Commercial uptake depends on biomarker testing adoption and label breadth.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000064 |
| Document: hcm-20260929x6k.htm | 0001648257-26-000064 |
| Document: 0001648257-26-000064-index-headers.html | 0001648257-26-000064 |
| Document: 0001648257-26-000064-index.html | 0001648257-26-000064 |
| Document: 0001648257-26-000064.txt | 0001648257-26-000064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $14.34 | awaiting T+20 | — | $14.27 (−0.49%) |
Oct 26, 2026 1d ago | 6-K | $15.41 | awaiting T+20 | — | $14.27 (−7.40%) |
Oct 26, 2026 1d ago | Press Release | $14.50 | awaiting T+20 | — | $14.27 (−1.59%) |
Oct 26, 2026 1d ago | Press Release | $14.34 | awaiting T+20 | — | $14.27 (−0.49%) |
Oct 21, 2026 6d ago | 6-K | $14.37 | awaiting T+20 | — | $14.27 (−0.70%) |
Sep 29, 2026 28d ago | 6-K | $14.15 | awaiting T+20 | — | $14.27 (+0.85%) |
Sep 28, 2026 28d ago | 6-K | $14.15 | awaiting T+20 | — | $14.27 (+0.85%) |
Sep 29, 2026 28d ago | Press Release | $14.63 | awaiting T+20 | — | $14.27 (−2.46%) |
Sep 24, 2026 4w ago | 6-K | $13.90 $14.28 | ▲ +2.73% | ▲ +3.15% | $14.27 (+2.66%) |
Sep 24, 2026 4w ago | Press Release | $13.94 $14.36 | ▲ +3.01% | ▲ +4.49% | $14.27 (+2.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers